Correlation Between Cue Biopharma and Tscan Therapeutics

Can any of the company-specific risk be diversified away by investing in both Cue Biopharma and Tscan Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cue Biopharma and Tscan Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cue Biopharma and Tscan Therapeutics, you can compare the effects of market volatilities on Cue Biopharma and Tscan Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cue Biopharma with a short position of Tscan Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cue Biopharma and Tscan Therapeutics.

Diversification Opportunities for Cue Biopharma and Tscan Therapeutics

-0.2

Correlation Coefficient

Cue Biopharma  Tscan Therapeutics

Good diversification

The 3 months correlation between Cue and Tscan is -0.2. Overlapping area represents the amount of risk that can be diversified away by holding Cue Biopharma and Tscan Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tscan Therapeutics and Cue Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cue Biopharma are associated (or correlated) with Tscan Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tscan Therapeutics has no effect on the direction of Cue Biopharma i.e., Cue Biopharma and Tscan Therapeutics go up and down completely randomly.

Pair Corralation between Cue Biopharma and Tscan Therapeutics

Considering the 90-day investment horizon Cue Biopharma is expected to under-perform the Tscan Therapeutics. In addition to that, Cue Biopharma is 1.54 times more volatile than Tscan Therapeutics. It trades about -0.17 of its total potential returns per unit of risk. Tscan Therapeutics is currently generating about 0.03 per unit of volatility. If you would invest  473.00  in Tscan Therapeutics on August 31, 2024 and sell it today you would earn a total of  4.00  from holding Tscan Therapeutics or generate 0.85% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Cue Biopharma  vs.  Tscan Therapeutics

Cue Biopharma

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Cue Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point.

Tscan Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Tscan Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Cue Biopharma and Tscan Therapeutics

The main advantage of trading using opposite Cue Biopharma and Tscan Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cue Biopharma position performs unexpectedly, Tscan Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tscan Therapeutics will offset losses from the drop in Tscan Therapeutics' long position.

The idea behind Cue Biopharma and Tscan Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.